DEXCOM INC - FORM 8-K - EX-99.1 - SELECTED FINANCIAL DATA - November 4, 2009

Attached files

file filename
EX-23.1 - CONSENT OF ERNST & YOUNG LLP - DEXCOM INCdex231.htm
EX-99.3 - FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA - DEXCOM INCdex993.htm
EX-99.2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OP - DEXCOM INCdex992.htm
8-K - FORM 8-K RESTATEMENT OF PRIOR YEAR FINANCIALS - DEXCOM INCd8k.htm

Exhibit 99.1

 

ITEM 6. SELECTED FINANCIAL DATA

The consolidated statements of operations data for the years ended December 31, 2008, 2007, and 2006 and the consolidated balance sheet data as of December 31, 2008 and 2007 have been derived from our audited consolidated financial statements included elsewhere in this annual report. The statements of operation data for the years ended December 31, 2005 and 2004 and the balance sheet data as of December 31, 2006, 2005 and 2004 have been derived from our audited financial statements not included in this annual report. The following selected financial data should be read in conjunction with our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and consolidated financial statements and related notes to those statements included elsewhere in this annual report.

As further discussed in Note 1 in our Notes to Consolidated Financial Statements included as Exhibit 99.3 in this Current Report on Form 8-K, our consolidated financial statements for the years ended December 31, 2008 and 2007 have been adjusted for the retrospective application of Financial Accounting Standards Board Staff Position No. APB 14-1, “Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)” (“FSP APB 14-1”). Consolidated financial statements prior to December 31, 2007 were not impacted by the adoption of FSP APB 14-1.

 

     Years Ended December 31,  
     2008     2007     2006     2005     2004  
     (in thousands, except per share data)  

Consolidated Statements of Operations Data:

           

Product revenue

    $ 8,108      $ 4,627      $ 2,170      $ —        $ —     

Development grant revenue

      1,730        —          —          —          —     
                                        

Total revenue

      9,838      $ 4,627      $ 2,170      $ —        $ —     

Product cost of sales

      13,383        12,736        10,959        —          —     

Development cost of sales

      1,984        —          —          —          —     
                                        

Total cost of sales

      15,367        12,736        10,959      $ —        $ —     
                                        

Gross margin (deficit)

      (5,529 )      (8,109 )      (8,789 )      —          —     

Operating expenses:

           

Research and development(1)

      19,629        16,131        19,419        26,770        12,470   

Selling, general and administrative(1)

      27,669        22,436        21,111        5,660        1,597   
                                        

Total operating expenses

      47,298        38,567        40,530        32,430        14,067   
                                        

Operating loss

      (52,827 )      (46,676 )      (49,319 )      (32,430 )      (14,067 ) 

Other income

      34        —          —          —          —     

Interest income

      1,220        3,782        2,815        1,662        121   

Interest expense

      (7,283 )      (5,560 )      (95 )      —          —     
                                        

Net loss

      (58,856 )      (48,454 )      (46,599 )      (30,768 )      (13,946 ) 
                                        

Accretion to redemption value of Series B and Series C redeemable convertible preferred stock

      —          —          —          (122 )      (3,235 ) 
                                        

Net loss attributable to common stockholders

    $ (58,856 )    $ (48,454 )    $ (46,599 )    $ (30,890 )    $ (17,181 ) 
                                        

Basic and diluted net loss per share attributable to common stockholders(2)

    $ (2.00 )    $ (1.71 )    $ (1.71 )    $ (1.63 )    $ (7.51 ) 
                                        

Shares used to compute basic and diluted net loss per share attributable to common stockholders(2)

      29,487        28,313        27,236        18,944        2,286   
                                        
     As of December 31,  
     2008     2007     2006     2005     2004  
     (in thousands)  

Consolidated Balance Sheet Data:

           

Cash and marketable securities

    $ 27,068      $ 64,323      $ 54,508      $ 50,525      $ 27,229   

Working capital

      17,062        58,844        52,126        43,939        25,705   

Total assets

      43,882        76,388        64,553        56,726        29,358   

Long term obligations

      48,354        38,009        2,118        —          —     

Redeemable convertible preferred stock

      —          —          —          —          76,974   

Total stockholders’ equity (deficit)

      (19,468 )      29,932        56,828        49,412        (49,310 ) 

 

1

 

(1)

For the years ended December 31, 2004 and 2005, certain prior period amounts have been reclassified to conform to current period presentation. The separate display of stock-based compensation expenses associated with research and development and selling, general, and administrative have been reclassified as components of research and development and selling, general, and administrative expenses.

(2)

See Note 2 of the notes to our consolidated financial statements for a description of the method used to compute basic and diluted net loss per share attributable to common stockholders.

 

2

DEXCOM INC Reports